Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways
about
Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatmentElotuzumab for the treatment of multiple myelomaSpotlight on elotuzumab in the treatment of multiple myeloma: the evidence to dateTreatment of multiple myeloma with the immunostimulatory SLAMF7 antibody elotuzumabMechanisms of action of therapeutic antibodies for cancerElotuzumab: a novel immune-stimulating therapy to treat multiple myeloma.Cetuximab intensifies the ADCC activity of adoptive NK cells in a nude mouse colorectal cancer xenograft model.Immune oppression array elucidating immune escape and survival mechanisms in uveal melanoma.Low-dose bortezomib increases the expression of NKG2D and DNAM-1 ligands and enhances induced NK and γδ T cell-mediated lysis in multiple myeloma.Talin-1 interaction network promotes hepatocellular carcinoma progression.Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma.The Clinical Pharmacology of Elotuzumab.Emerging combination therapies for the management of multiple myeloma: the role of elotuzumab.Immunologic approaches for the treatment of multiple myeloma.Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab.Emerging antibodies for the treatment of multiple myeloma.A phase 2 safety study of accelerated elotuzumab infusion, over less than 1 h, in combination with lenalidomide and dexamethasone, in patients with multiple myeloma.Efficacy and safety of elotuzumab for the treatment of multiple myeloma.Treatment options for relapse after autograft in multiple myeloma - report from an EBMT educational meeting.Potential therapeutic targets in plasma cell disorders: A flow cytometry study.Therapeutic effect of lymphokine-activated killer cells treated with low-dose ionizing radiation on osteosarcomaInflammatory and Anti-Inflammatory Equilibrium, Proliferative and Antiproliferative Balance: The Role of Cytokines in Multiple Myeloma.Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against.A review discussing elotuzumab and its use in the second-line plus treatment of multiple myeloma.Evolutionary biology of high-risk multiple myeloma.Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs.Antibody-based delivery of tumor necrosis factor (L19-TNFα) and interleukin-2 (L19-IL2) to tumor-associated blood vessels has potent immunological and anticancer activity in the syngeneic J558L BALB/c myeloma model.Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 study.Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment.Tumor immunotherapy: New aspects of natural killer cells.Elotuzumab for the Treatment of Relapsed or Refractory Multiple Myeloma, with Special Reference to its Modes of Action and SLAMF7 Signaling.The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and -independent mechanisms.Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma
P2860
Q26738944-86BAABE8-A228-4AF8-B9E2-30E6A5AA66D5Q26740278-3128A2F0-E6E4-4AAF-B1A2-1E72B1714BC9Q28076147-C7EA0B2A-87EB-4E1E-A750-49002DE23E3CQ28078993-55ACBD69-1E22-4522-B9ED-AA6C393769E5Q28385366-09BEF1C6-0BB5-4C3E-A4DC-E583906EF0E3Q30249513-70D9535F-297F-4F88-94F0-464E4AFBD3BAQ37204600-9EB1FB89-2B76-4D5D-B3A5-D1E840CC8F31Q37500476-18395BF4-4B73-4DE9-939E-5285C31FF667Q37701514-E72537BE-A90A-4909-94CD-EE8BBADEF430Q38438026-3A7F98DF-5FAD-4B62-AC5E-2A9FD6793304Q38526452-47431253-E982-435E-A79D-126C09D8F2FFQ38639376-CA04FB6B-D36C-43B3-8D3E-FC1EE7BF0346Q38661370-EB6310E1-F8DC-4CC6-922D-890D61F24860Q38692244-2B142DF6-D198-49FE-B331-AC9554CB1CFAQ38737970-A8782137-707E-44F1-ADA6-656FB4E5F42EQ38809499-8C6A5461-78BA-4455-9638-523B176EDB85Q38838239-8B83A1B4-CF94-44BD-9D1D-7B2718962B0CQ38954303-8F492DEB-145C-4019-AE86-EDA952CA72E0Q39070515-527494F7-BD7D-4FC6-89E8-77AB0E2C7561Q39369772-90E9DFE6-8AF8-4978-9E92-27507534024CQ40212706-E1B19584-FFC6-4723-BBA0-B74DED3C2083Q42364140-7AACC052-7E25-4F6A-A240-1E0CA6EBCAF9Q45756098-91D500A3-1DB7-420A-B2FC-919AFAA6A0B7Q47418005-4EC6B0E8-BA5C-46DF-9CC4-98151B24D42AQ47865755-A0649F11-C13C-40E7-95F1-1ADC8F8581D4Q47913337-2DBF6C03-4C58-4948-AAA1-1EA01EE5B82BQ49830211-A6546C04-CF4B-4167-AC67-1D8AF9098845Q50073502-BC5773E3-963D-4E52-A68B-BB7763DEAED5Q51325371-7318AFA3-CF61-42C3-ACD2-159FC0AAA91CQ52658085-F0DAE72A-A307-4BD7-BAAA-50FC3816F569Q55107050-82157654-F2EB-4A8B-8898-E4BA5A97355CQ55310350-9C15C326-8641-4C76-870C-CE0AF0EB9F3DQ55409204-EF7437B8-C1FF-45FD-A9BE-53015F7DBE1CQ59136966-6CF2F95E-0D2F-4F68-B05C-FC7BEEA15CE7
P2860
Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Elotuzumab enhances natural ki ...... terleukin-2 and TNF-α pathways
@ast
Elotuzumab enhances natural ki ...... terleukin-2 and TNF-α pathways
@en
Elotuzumab enhances natural ki ...... terleukin-2 and TNF-α pathways
@nl
type
label
Elotuzumab enhances natural ki ...... terleukin-2 and TNF-α pathways
@ast
Elotuzumab enhances natural ki ...... terleukin-2 and TNF-α pathways
@en
Elotuzumab enhances natural ki ...... terleukin-2 and TNF-α pathways
@nl
prefLabel
Elotuzumab enhances natural ki ...... terleukin-2 and TNF-α pathways
@ast
Elotuzumab enhances natural ki ...... terleukin-2 and TNF-α pathways
@en
Elotuzumab enhances natural ki ...... terleukin-2 and TNF-α pathways
@nl
P2093
P2860
P1476
Elotuzumab enhances natural ki ...... terleukin-2 and TNF-α pathways
@en
P2093
Audie G Rice
Balaji Balasa
Debra T Chao
Melvin Fox
Michael D Robbins
Nicole A Belmar
P2860
P2888
P356
10.1007/S00262-014-1610-3
P577
2014-10-07T00:00:00Z
P5875
P6179
1050837686